PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D change of 13.21% versus flat Healthcare spending. Walter Schloss would verify adequacy.
-38.56%
G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-7.06%
Operating expenses reduction while Healthcare median is 0.97%. Seth Klarman would investigate advantages.
-7.06%
Total costs reduction while Healthcare median is 1.34%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
D&A reduction while Healthcare median is 0.74%. Seth Klarman would investigate efficiency.
7.02%
EBITDA change of 7.02% versus flat Healthcare. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Income change of 7.06% versus flat Healthcare. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
148.79%
Other expenses growth exceeding 1.5x Healthcare median of 1.80%. Jim Chanos would check for issues.
10.36%
Income change of 10.36% versus flat Healthcare. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.36%
Income change of 10.36% versus flat Healthcare. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
28.30%
EPS growth exceeding 1.5x Healthcare median of 2.57%. Joel Greenblatt would investigate advantages.
28.30%
Diluted EPS growth exceeding 1.5x Healthcare median of 2.53%. Joel Greenblatt would investigate advantages.
24.68%
Share count reduction below 50% of Healthcare median of 0.20%. Jim Chanos would check for issues.
24.68%
Diluted share reduction below 50% of Healthcare median of 0.27%. Jim Chanos would check for issues.